comparemela.com

Latest Breaking News On - மதிப்பு ஆராய்ச்சி - Page 19 : comparemela.com

investing: Pad up for test innings, not T20 to score big on SIP

An age-wise analysis of SIP accounts for December points out that of the 34.7 million SIP accounts, 31.84 per cent are for less than a year only, with another 21 per cent run for a time frame of 1-2 years. Only 7.67 per cent of SIP accounts continue for more than 5 years.

SIP: Pad up for a test innings, not T20 to score big returns on SIP pitch

An age-wise analysis of SIP accounts for December points out that of the 34.7 million SIP accounts, 31.84 per cent are for less than a year only, with another 21 per cent run for a time frame of 1-2 years. Only 7.67 per cent of SIP accounts continue for more than 5 years.

Returning Unitholders Money: The First Of Many Steps Needed For Franklin Templeton s Image Makeover

Returning unitholders money: The first of many steps needed for Franklin Templeton s image makeover Franklin Templeton also faces the uphill task of getting its equity funds back in the reckoning January 29, 2021 / 02:19 PM IST Templeton India Growth Fund will complete 25 years later this year. It was the first mutual fund scheme rolled out by Franklin Templeton Mutual Fund (FT MF) when the fund house set shop in India in 1996. But the celebrations are bound to be muted on account of another anniversary – it will be one year in April since the fund house decided to wind up six of its debt schemes.

Some NJ COVID patients benefit from hydroxychloroquine, study shows

A new Hackensack Meridian Health study shows that people with mild symptoms of COVID-19 may be helped by a controversial drug that had been widely used in the early days of the pandemic before several studies questioned its benefits and safety. The recently published study looked at a group of people treated as outpatients last year and found that those who received an anti-inflammatory drug, hydroxychloroquine, which is often used for malaria, were significantly less likely to end up in the hospital. Doctors who conducted the study say the findings suggest that it should be tested further. We make it clear we can t recommend it to be given, said Andrew Ip, a lymphoma physician and director of the Division of Outcomes and Value Research at the

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.